Blood Safety (nvCJD)

Precautionary Measures To Reduce Theoretical Risk of Disease from Blood Products

Published in Medical Letter on the CDC and FDA, August 30th, 1999

The U.S. Food and Drug Administration (FDA) issued guidance to blood establishments to reduce the theoretical risk of transmission of new variant Creutzfeldt-Jakob Disease (nvCJD) to recipients of blood products.

This guidance, a precautionary measure, asks blood centers to exclude potential donors who have spent six or more cumulative months in the United Kingdom between January 1, 1980, and December 31, 1996, from donating blood.

The FDA's guidance was developed in parallel with Canada's health ministry, Health Canada, which issued similar guidance for its blood establishments.

The FDA expects blood centers to implement the new...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (1999-08-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry